Can Neuroimaging Be Used as a Biomarker in ADHD? 

The use of neuroimaging biomarkers in ADHD research has opened exciting possibilities for understanding the brain’s structure and function in affected individuals. Tools like MRI, fMRI, and DTI are being explored not just for scientific insight, but also for their potential as biomarkers to aid in diagnosis, monitoring, and personalised treatment planning. 

What Brain Scans Show in ADHD 

Studies using structural MRI have consistently shown differences in brain regions tied to attention, impulse control, and executive function, particularly the prefrontal cortex, basal ganglia, and cerebellum. Children with ADHD often have smaller total brain volumes and delayed cortical maturation compared to neurotypical peers. 

Functional MRI (fMRI) provides additional insight by tracking real-time brain activity. People with ADHD often show reduced activity in the default mode network (DMN) and altered connectivity in networks that govern attention and inhibition. Meanwhile, diffusion tensor imaging (DTI) reveals microstructural differences in white matter tracts, suggesting altered neural communication pathways. 

Can These Scans Be Used Clinically? 

Although these findings are robust at the group level, neuroimaging biomarkers are not yet reliable enough for routine clinical diagnosis. Variability between individuals and the high cost of brain scans make them impractical for everyday use for now. However, ongoing research aims to refine these methods into tools that could complement behavioural assessments in complex cases. 

Conclusion 

Neuroimaging biomarkers offer a promising window into the ADHD brain and may one day enhance diagnosis and treatment. Visit providers like ADHD Certify for personal consultations and information on cutting-edge neuroimaging tools in ADHD care.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Genetic studies and biomarkers.